Q-linea continues enhancing the pipeline of prospects, from entering tenders to close to the final c...
NoHo Partners' Q3 2024 results missed Vara Research expectations on several items, but the guidance ...
Taaleri's Q3 2024 results were solid on an underlying basis and fairly in line with our estimates.
A weaker-than-expected Q3 on almost all parameters Another PW as extraction of synergies proves cost...
Deliveries and sales in line, somewhat lower costs than expected Update on development studies and s...
Demand weak as expected, but improved by quarter-end Comps also ease in Q4, return to order growth l...
Q3: Revenues 1% below, EBIT DKK -2m vs. ABGSCe +12m FY'24 guidance downgraded again Consensus likely...
MoveByBike Europe AB ("MoveByBike" eller "Bolaget") meddelade den 5 november 2024 att partnerskapet ...
Q3 results in-line, cash burn of DKK 27m Small new design win (~1k units), reiterates target of 4-6 ...
Q3 adj. EBIT of GBP 15m, below ABGSCe at GBP 19m Beat on Asset Management, miss on Capital Markets U...
Sales -2%, adj. EBIT +4m vs. FactSet consensus Better EBIT largely driven by improved cost control E...
Taaleri reported recurring revenues of EUR 9.7m (-6% y/y), 4% below our estimate, mostly explained b...
Orders -2%, sales +1%, EBITA -18% vs. ABGSCe Unspecified non-recurring items related to improvement ...
Redeye comments on the US CMS rate change for 2025.
Redeye provides an initial comment on the Q3 2024 report from Cheffelo, which came in below our esti...
